HK Stock Connect Daily Report: Nexchip formally added to HK Stock Connect, innovative drug sector driven by dense earnings catalysts - 20260807
I. Market Overview
On 7 August, the three major Hong Kong indices opened lower and closed higher. The Hang Seng Index rose 0.54% to 25,668.03 points, the Hang Seng TECH Index rose 0.78% and the Hang Seng China Enterprises Index rose 0.39%. Total daily turnover was HKD 259.686 billion, slightly up from the previous trading day.
On the trading front, pharmaceutical stocks led the gains, with ZAI LAB (09688) up 18.38%, WUXI BIO (02269) up 10.83% and WUXI APPTEC (02359) up 7.01%. PCB concepts rose across the board, with DELTON (01989) up 10.93% and VGT (02476) up 10.91%, as Goldman Sachs sharply raised its forecasts for the AI server PCB and CCL markets. The twin large-model titans climbed again, with Z.AI (02513) up 14.63% and MINIMAX-W (00100) up 9.83%, as DeepSeek announced API price increases, accelerating the convergence of low-price competition in the industry. Solar stocks rebounded broadly, with XINTE ENERGY (01799) up 13.53%, as eight major polysilicon producers signed an anti-involution initiative. Gold stocks extended gains in the afternoon, with ZIJIN MINING (02899) up 3.12%. Airline stocks came under pressure, with MGM CHINA (02282) down 7.76%.
Southbound capital recorded a net sell of HKD 778 million on the day, of which Stock Connect (Shanghai) posted a net buy of HKD 571 million and Stock Connect (Shenzhen) a net sell of HKD 1.349 billion.
II. HK Stock Connect Stock Rankings
2.1 HK Stock Connect Stock Gainers and Decliners
|
Category |
Stock Code |
Stock Name |
Change (%) |
Close (HKD) |
Turnover (HKD 100mn) |
|
Gainer 1 |
02565.HK |
PEGBIO CO-B |
23.59 |
6.58 |
4.19 |
|
Gainer 2 |
09688.HK |
ZAI LAB |
18.38 |
17.20 |
4.79 |
|
Gainer 3 |
00975.HK |
MONGOL MINING |
16.85 |
8.71 |
0.93 |
|
Gainer 4 |
01548.HK |
GENSCRIPT BIO |
16.18 |
22.98 |
16.46 |
|
Gainer 5 |
02513.HK |
Z.AI |
14.63 |
1246.00 |
106.37 |
|
Decliner 5 |
02706.HK |
HAIZHI TECH GP |
-5.44 |
48.18 |
4.42 |
|
Decliner 4 |
02589.HK |
AUNTEA JENNY |
-5.48 |
117.30 |
0.51 |
|
Decliner 3 |
01783.HK |
ENVISION GREEN |
-5.94 |
5.15 |
1.24 |
|
Decliner 2 |
01117.HK |
CH MODERN D |
-6.94 |
1.48 |
1.26 |
|
Decliner 1 |
02282.HK |
MGM CHINA |
-7.76 |
10.22 |
1.41 |
Source: Wind, HKEX. The content of this article is for the objective presentation of data only and does not constitute any investment advice, nor does it represent a recommendation for or value judgment on any security. The market involves risks; investment requires caution.
2.2 HK Stock Connect Active Stocks (ranked by southbound turnover)
|
Rank |
Stock Code |
Stock Name |
Southbound Turnover (HKD 100mn) |
Southbound Net Buy (HKD 100mn) |
Change (%) |
|
1 |
02513.HK |
Z.AI |
96.52 |
0.28 |
14.63 |
|
2 |
00100.HK |
MINIMAX-W |
75.43 |
22.26 |
9.83 |
|
3 |
01888.HK |
KB LAMINATES |
72.56 |
6.34 |
9.91 |
|
4 |
09988.HK |
ALIBABA-W |
50.84 |
-16.84 |
-0.48 |
|
5 |
03986.HK |
GIGADEVICE |
48.72 |
4.29 |
6.80 |
|
6 |
00700.HK |
TENCENT |
45.63 |
-21.88 |
-0.08 |
|
7 |
06869.HK |
YOFC |
44.09 |
-0.36 |
5.80 |
|
8 |
00981.HK |
SMIC |
41.37 |
3.98 |
2.37 |
|
9 |
01347.HK |
HUA HONG GRACE |
31.17 |
1.88 |
3.29 |
|
10 |
00148.HK |
KINGBOARD HLDG |
21.95 |
0.53 |
6.31 |
Source: Wind, HKEX. The content of this article is for the objective presentation of data only and does not constitute any investment advice, nor does it represent a recommendation for or value judgment on any security. The market involves risks; investment requires caution.
III. HK Stock Connect-related A-share ETF Rankings
3.1 HK Stock Connect-related A-share ETF Gainers and Decliners
|
Category |
Code |
Short Name |
Change (%) |
Turnover (RMB 100mn) |
|
Gainer 1 |
520700 |
Wanjia CSI HK Equities Innovative Drugs ETF |
6.58 |
9.49 |
|
Gainer 2 |
513780 |
Invesco Great Wall CSI HK Equities Innovative Drugs ETF |
6.41 |
9.53 |
|
Gainer 3 |
520970 |
Harvest CSI HK Equities Innovative Drugs ETF |
6.31 |
1.55 |
|
Gainer 4 |
159366 |
Maxwealth CSI HK Equities Health Care Theme ETF |
5.88 |
2.84 |
|
Gainer 5 |
520510 |
ChinaAMC CSI HK Equities Health Care Theme ETF |
5.86 |
2.24 |
|
Decliner 5 |
513070 |
E Fund CSI HK Equities Consumption Theme ETF |
-0.80 |
1.31 |
|
Decliner 4 |
159118 |
ChinaAMC S&P HK Equities Low Volatility Dividend ETF |
-0.83 |
0.04 |
|
Decliner 3 |
159545 |
E Fund Hang Seng HK High Dividend Low Volatility ETF |
-0.84 |
1.42 |
|
Decliner 2 |
159245 |
Fullgoal CNI HK Equities Consumption Theme ETF |
-0.87 |
0.03 |
|
Decliner 1 |
159735 |
Yinhua CSI HK Equities Consumption Theme ETF |
-0.88 |
0.43 |
Source: Wind. The content of this article is for the objective presentation of data only and does not constitute any investment advice, nor does it represent a recommendation for or value judgment on any security. The market involves risks; investment requires caution.
3.2 HK Stock Connect-related A-share ETF Active Rankings (ranked by turnover)
|
Rank |
Code |
Short Name |
Tracking Index |
Turnover (RMB 100mn) |
Turnover Rate (%) |
Change (%) |
|
1 |
159570 |
China Universal CNI HK Equities Innovative Drugs ETF |
CNI HK Equities Innovative Drugs Index |
27.87 |
11.18 |
5.03 |
|
2 |
159131 |
Hwabao CSI HK Equities Information Technology Integration ETF |
CSI HK Equities Information Technology Integration Index (CNY) |
21.87 |
89.50 |
2.87 |
|
3 |
159567 |
Yinhua CNI HK Equities Innovative Drugs ETF |
CNI HK Equities Innovative Drugs Index |
17.20 |
22.85 |
4.92 |
|
4 |
159792 |
Fullgoal CSI HK Equities Internet ETF |
CSI HK Equities Internet Index |
17.14 |
3.85 |
0.16 |
|
5 |
159316 |
E Fund Hang Seng HK Innovative Drugs ETF |
Hang Seng HK Innovative Drugs Index |
13.47 |
20.62 |
4.78 |
|
6 |
513780 |
Invesco Great Wall CSI HK Equities Innovative Drugs ETF |
CNI HK Equities Innovative Drugs Index |
9.53 |
32.98 |
6.41 |
|
7 |
520700 |
Wanjia CSI HK Equities Innovative Drugs ETF |
CNI HK Equities Innovative Drugs Index |
9.49 |
131.15 |
6.58 |
|
8 |
159217 |
ICBCCS CNI HK Equities Innovative Drugs ETF |
CNI HK Equities Innovative Drugs Index |
7.91 |
11.03 |
5.40 |
|
9 |
159506 |
Fullgoal Hang Seng HK Equities Innovative Drugs And Health Care ETF |
Hang Seng HK Equities Innovative Drugs And Health Care Index |
7.43 |
22.71 |
5.07 |
|
10 |
513040 |
E Fund CSI HK Equities Internet ETF |
CSI HK Equities Internet Index |
7.19 |
10.37 |
-0.10 |
Source: Wind. The content of this article is for the objective presentation of data only and does not constitute any investment advice, nor does it represent a recommendation for or value judgment on any security. The market involves risks; investment requires caution.
IV. Industry and Corporate Updates
1. Nexchip formally added to HK Stock Connect, effective 7 August
On 7 August, the Shenzhen Stock Exchange announced adjustments to the HK Stock Connect eligible securities list, adding Nexchip (02249.HK) with effect from that day. Nexchip is principally engaged in semiconductor wafer foundry and is an A-share STAR Market listed company (688249.SH); its addition means mainland investors can directly trade its H shares through the Stock Connect channel. The Shanghai Stock Exchange also added Nexchip to the southbound list under Shanghai-Hong Kong Stock Connect on 6 August.
2. BeiGene's H1 net profit soars 627%, sharply raising full-year revenue guidance
On 7 August, BeiGene (06160.HK) announced that net profit attributable to owners of the parent for the first half of 2026 reached RMB 3.271 billion, up 627.1% year-on-year, with total operating revenue of RMB 22.220 billion, up 26.8% year-on-year. The Company raised its 2026 revenue forecast to RMB 44.9 billion to RMB 46.2 billion. BeiGene is an HK Stock Connect eligible stock, and its results drove the HK Stock Connect innovative drug sector to strengthen across the board.
3. RemeGen issues profit alert, achieving large-scale interim profitability for the first time
On 7 August, RemeGen (09995.HK) issued a profit alert, expecting first-half operating revenue of approximately RMB 5.85 billion, up more than 4.3 times year-on-year, with net profit attributable to owners of the parent of RMB 4.7 billion and net profit attributable to owners of the parent excluding non-recurring items of approximately RMB 4.3 billion, marking the first large-scale interim profitability since listing. The growth was mainly driven by continued increases in domestic sales of core commercialised products Telitacicept and Disitamab Vedotin, as well as the recognition of substantial technology licensing income from the exclusive out-licensing agreement with AbbVie for overseas rights to RC148 (a PD-1/VEGF bispecific antibody), with total transaction value of up to USD 5.6 billion. RemeGen is an HK Stock Connect eligible stock.
4. Baili Tianheng files with HKEX for the fourth time, seeking A+H dual listing
According to HKEX documents disclosed on 6 August, Sichuan Baili Tianheng Pharmaceutical Co., Ltd. has submitted a listing application to the Main Board of HKEX, seeking an A+H dual listing. The Company listed on the STAR Market of the Shanghai Stock Exchange in January 2023 (688506.SH). This is Baili Tianheng's fourth attempt at a Hong Kong IPO after its previous three filings lapsed.
5. NASN TECH officially lists on HKEX, Hong Kong public offering oversubscribed over 2,500 times
On 7 August, NASN TECH (02261.HK), an intelligent driving wire-controlled braking solutions provider, officially listed on the Main Board of HKEX. The Company offered 57,594,500 H shares globally at an offer price of HKD 10.42 per share, with the Hong Kong public offering oversubscribed by 2,513.54 times, reflecting a strong market response. Focusing on intelligent driving wire-controlled braking, NASN TECH was one of China's top three domestic wire-controlled braking solutions providers by 2025 sales volume.
V. Market Notes
Eligible securities list adjustment announcement
On 7 August, the Shenzhen Stock Exchange announced adjustments to the HK Stock Connect eligible securities list, adding Nexchip (02249.HK) with effect from that day. No securities were removed in this adjustment.
Trading calendar
No approaching market closure days.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
